HB1443 creates the Prescription Drug Affordability Board Act, establishing a new state board and a stakeholder council to review prescription drug costs and address affordability challenges in Illinois. The Board would be composed of five gubernatorial appointees with Senate confirmation, supported by a 15-member stakeholder council appointed by legislative leaders and the Governor. The Board is authorized to meet publicly, hire staff and contractors, adopt rules, collect information, and conduct affordability reviews of selected prescription drugs, including brand-name drugs, biologics, biosimilars, and certain generic drugs with high prices or large price increases.
The bill gives the Board authority to establish upper payment limits for drugs it finds to be causing affordability problems, subject to a range of procedural and substantive limits. It requires the Board to consider access, patient costs, market competition, manufacturer pricing, shortages, and impacts on underserved communities, and it bars the use of certain cost-effectiveness methods based on quality-adjusted life years. The bill also requires an operational plan before limits are imposed, provides for public comment and disclosure, and sets appeal and judicial review procedures for Board decisions. The Act is temporary: it repeals itself five years after the effective date, and the related fund section in the State Finance Act is also repealed on that timeline.
HB1443 would add a new regulatory structure to Illinois law governing prescription drug pricing, including new provisions in the State Finance Act for a Prescription Drug Affordability Board Fund. It would affect the Illinois Insurance Code, the Public Aid Code, the State Employees Group Insurance Act, the Freedom of Information Act, the Open Meetings Act, and administrative review procedures by creating new duties, disclosure rules, and enforcement mechanisms. It also authorizes annual assessments on drug manufacturers to fund the Board, caps annual Board spending at $750,000, and gives the Attorney General enforcement authority.
Based on the bill text alone and the absence of committee transcripts or recorded votes, the overall posture of the bill appears strongly pro-affordability and consumer-focused. The legislation is structured to emphasize transparency, public input, conflict-of-interest safeguards, and protections for access to medications and pharmacies, suggesting an effort to build support around drug-cost relief while addressing implementation concerns. No recorded votes or discussion excerpts are available here to indicate opposition or amendment debate.
The main points of contention likely center on the Board’s authority to set upper payment limits, the potential effect on manufacturers, wholesalers, pharmacies, and pharmacy benefit managers, and whether state-imposed price limits could disrupt supply or access. The bill anticipates these concerns by requiring an operational plan, allowing suspension of limits during shortages, protecting dispensing fees, and limiting the Board’s use of certain cost-effectiveness analyses. Another likely issue is the funding mechanism: manufacturers would pay annual assessments to support the Board, which may draw criticism from the pharmaceutical industry. The bill also contains carve-outs and special treatment for Medicaid and state employee plans unless state cost savings are shown, which could be a point of policy debate.